Literature DB >> 28803677

Indole-fused azepines and analogues as anticancer lead molecules: Privileged findings and future directions.

Ashok K Singh1, Vinit Raj1, Sudipta Saha2.   

Abstract

The search for new lead compounds of simple structure, displaying highest quality anti-tumor potency with new mechanisms of action and least adverse effects is the major intention of cancer drug discovery now a days. For the time being, indole-fused azepines emerged as a simple class of compounds prolifically designed with strong pharmacological significances in particular of cancer protecting ability. In the recent years from the efforts of our research group, indole-fused heteroazepines, a simple structural class achieved by fusion of indole with oxygen, sulphur and nitrogen containing heteroazepine rings, have known for its superior outcomes in cancer treatment. Surprisingly, the chemistry and biology of these unique families with an amazing role in cancer drug discovery has remained broadly unexplored. This short review is consequently an endeavor to highlight the preliminary ideas over this structural class and to draw the medical attention towards future development of indole-fused azepines and analogues for their promising function in cancer drug discovery.
Copyright © 2017 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Azepine; Cancer drug discovery; Design strategy and structure activity relationship; Indole; Indole-fused azepines; Synthetic strategies

Mesh:

Substances:

Year:  2017        PMID: 28803677     DOI: 10.1016/j.ejmech.2017.07.042

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  6 in total

1.  Novel Indole-fused benzo-oxazepines (IFBOs) inhibit invasion of hepatocellular carcinoma by targeting IL-6 mediated JAK2/STAT3 oncogenic signals.

Authors:  Ashok K Singh; Archana S Bhadauria; Umesh Kumar; Vinit Raj; Amit Rai; Pranesh Kumar; Amit K Keshari; Dinesh Kumar; Biswanath Maity; Sneha Nath; Anand Prakash; Sudipta Saha
Journal:  Sci Rep       Date:  2018-04-12       Impact factor: 4.379

2.  Highly Reactive Cyclic Monoaryl Iodoniums Tuned as Carbene Generators Couple with Nucleophiles under Metal-Free Conditions.

Authors:  Haiwen Wang; Liyun Liang; Zhirong Guo; Hui Peng; Shuang Qiao; Nemai Saha; Daqian Zhu; Wenbin Zeng; Yunyun Chen; Peng Huang; Shijun Wen
Journal:  iScience       Date:  2020-06-23

3.  Inhibition of Microtubule Dynamics in Cancer Cells by Indole-Modified Latonduine Derivatives and Their Metal Complexes.

Authors:  Christopher Wittmann; Anastasiia S Sivchenko; Felix Bacher; Kelvin K H Tong; Navjot Guru; Thomas Wilson; Junior Gonzales; Hartmut Rauch; Susanne Kossatz; Thomas Reiner; Maria V Babak; Vladimir B Arion
Journal:  Inorg Chem       Date:  2022-01-07       Impact factor: 5.165

4.  Ready access to 7,8-dihydroindolo[2,3-d][1]benzazepine-6(5H)-one scaffold and analogues via early-stage Fischer ring-closure reaction.

Authors:  Irina Kuznetcova; Felix Bacher; Daniel Vegh; Hsiang-Yu Chuang; Vladimir B Arion
Journal:  Beilstein J Org Chem       Date:  2022-01-26       Impact factor: 2.883

Review 5.  β-Carboline-based molecular hybrids as anticancer agents: a brief sketch.

Authors:  Jay Prakash Soni; Yogesh Yeole; Nagula Shankaraiah
Journal:  RSC Med Chem       Date:  2021-03-24

6.  Highly Antiproliferative Latonduine and Indolo[2,3-c]quinoline Derivatives: Complex Formation with Copper(II) Markedly Changes the Kinase Inhibitory Profile.

Authors:  Christopher Wittmann; Felix Bacher; Eva A Enyedy; Orsolya Dömötör; Gabriella Spengler; Christian Madejski; Jóhannes Reynisson; Vladimir B Arion
Journal:  J Med Chem       Date:  2022-02-01       Impact factor: 7.446

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.